Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Breast Cancer Guidance Paves Way For Accelerated Approval With One Trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA draft guidance lays out use of pathologic complete response to support accelerated approval of drugs for women with high-risk, early-stage breast cancer. Pathway allows for initial approval based on one pivotal study, which could be extended to assess survival and confirm clearance.


Related Content

Cancer Trial Endpoints: Minimal Residual Disease Eyed As Surrogate
Genetic Exposé Of Ovarian Cancer Prompts Radical Rethink Of Trial Design
Buoyed By T-DM1 EMILIA Data, Roche Leaps To Early Breast Cancer Trial
FDA Expanding Accelerated Approval Through Guidance, Collaboration
TREAT Act Wants Accelerated Approval Change, But Uses Existing Language
Expedited Approval Pathway Concept Draws Strong Support But Different Proposals
FDA Biomedical Innovation Initiative Draws On Familiar Themes
Biomarkers Consortium Launches Adaptive Trial To Test Targeted Breast Cancer Drugs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts